Intercell enters into strategic partnership with Wyeth for the use of its IC31TM adjuvant in various infectious disease vaccines
Intercell AG announced that it has closed a worldwide nonexclusive agreement under which Wyeth has the right to use Intercell's fully synthetic novel adjuvant IC31TM in various selected infectious disease vaccine programs. Under the agreement, Intercell may be entitled to receive up to USD 77 million in upfront, option and milestone payments as well as royalties on product net sales.
Vaccines, based on antigens alone, are not sufficient to provide full protection. Adjuvants are needed to educate the immune system to recognize and eliminate the pathogens efficiently. IC31TM is an adjuvant that induces Tcell and Bcell responses by using a unique synthetic formulation which combines the immunostimulating properties of an antimicrobial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two component solution can be simply mixed with antigens; no conjugation is required.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.